La taille du marché des tests de dépistage du cancer héréditaire est estimée à 9 840,52 millions de dollars US d'ici 2027, contre 3 967,74 millions de dollars US en 2018 ; il devrait croître à un TCAC de 11,1 % entre 2019 et 2027.
Un cancer héréditaire est tout cancer causé par une mutation génétique héréditaire. On sait que des variantes nocives de certains gènes sont associées à un risque accru de développer un cancer. Les tests génétiques aident à estimer le risque d'un individu de développer un cancer au cours de sa vie. Cela peut être fait en recherchant des mutations dans ses gènes, ses chromosomes ou ses protéines. Des tests génétiques sont disponibles pour quelques types de cancer. Ceux-ci incluent le cancer du sein, le cancer des ovaires, le cancer du côlon, le cancer de la thyroïde, le cancer de la prostate, le cancer du pancréas, le mélanome, le sarcome, le cancer du rein et le cancer de l'estomac.
Le marché des tests de dépistage du cancer héréditaire Cette tendance est attribuée à lattention croissante portée à la R&D sur les tests génétiques pour analyser la corrélation entre le cancer et la séquence génétique, à la prévalence croissante du cancer héréditaire et à laugmentation de la demande de kits de tests ADN. Cependant, des réglementations strictes concernant le diagnostic du cancer peuvent entraver la croissance du marché.
Aperçus stratégiques
Régions lucratives pour le marché des tests de dépistage du cancer héréditaire
Aperçus du marché< /h3> Prévalence croissante du cancer héréditaire
Le cancer est une maladie génétique causée par des variations définies des gènes qui régissent le fonctionnement des cellules, affectant particulièrement leur croissance et leur réplication. Les mutations génétiques héréditaires sont à lorigine denviron 5 à 10 % de tous les cancers. Les chercheurs ont associé des mutations dans des gènes particuliers à plus de 50 syndromes cancéreux héréditaires affectant les individus développant certains cancers. Selon l'Organisation mondiale de la santé, le cancer a causé environ 9,6 millions de décès dans le monde en 2018. De plus, selon les prévisions du National Cancer Institute, en 2018, environ 1 735 350 nouveaux cas de cancer seraient diagnostiqués aux États-Unis. La prévalence croissante du cancer du sein dans le monde est une préoccupation majeure. Selon l'Organisation mondiale de la santé, environ 2,09 millions de cas de cancer du sein ont été signalés dans le monde en 2018. Cependant, selon breastcancer.org, en 2018, aux États-Unis, plus de 3,1 millions de femmes avaient des antécédents de cancer du sein.
De plus, environ 5 à 10 % des cancers du sein sont liés aux gènes mutés hérités des parents. Les variations des gènes BRCA1 et BRCA2 sont répandues. Les femmes porteuses d'une mutation BRCA1 ont un risque d'environ 72 % au cours de leur vie de développer un cancer du sein, tandis que celles porteuses de la mutation BRCA2 ont un risque d'environ 69 %. En outre, lAPAC est confrontée au problème de la prévalence croissante du cancer. La Chine, le Japon, lInde, Taïwan, la Corée du Sud, la Malaisie, Singapour, la Thaïlande, les Philippines, le Sri Lanka, le Vietnam, lIndonésie, la Mongolie, le Laos et le Cambodge sont les 15 principaux pays où lincidence du cancer est élevée. Selon les données de lInstitut national de prévention et de recherche sur le cancer (NICPR), en 2018, le cancer a causé 784 821 décès en Inde. Par conséquent, la prévalence croissante du cancer entraîne une croissance constante du cancer héréditaire, entraînant ainsi la croissance du marché des tests de cancer héréditaire.
Informations basées sur les types de diagnostic
Le marché mondial des tests de cancer héréditaire , en fonction du type de diagnostic, est divisé en biopsie et imagerie. Le segment des biopsies représentait une part plus importante en 2018. Cependant, le segment de limagerie devrait connaître une croissance plus rapide au cours de la période 2019-2027. Le segment des biopsies devrait croître en raison de la prévalence croissante du cancer, de la demande croissante de chirurgies mini-invasives et des initiatives entreprises par les gouvernements et les organisations de santé mondiales.
Informations basées sur la technologie
Le Le marché mondial des tests de dépistage du cancer héréditaire, basé sur la technologie, est segmenté en séquençage, PCR et micropuces. Le segment du séquençage était le plus important parmi les sous-segments technologiques en 2018 et devrait continuer à connaître une croissance significative au cours de la période 2019-2027. Le segment du séquençage devrait croître en raison de l'allocation de fonds par divers organismes gouvernementaux et de l'utilisation du NGS dans le séquençage et le séquençage ciblé à des fins multiples, telles que la détection du cancer héréditaire.
Informations basées sur l'utilisateur final< /h3>
Le marché mondial du dépistage du cancer héréditaire, en fonction de l'utilisateur final, est segmenté en centres de diagnostic, hôpitaux et cliniques. Les centres de diagnostic devraient connaître la plus forte croissance au cours de la période de prévision. Cependant, le segment hospitalier représentait la plus grande part en 2018 et devrait poursuivre sur une tendance similaire au cours de la période de prévision. Le segment des centres de diagnostic devrait croître en raison dun diagnostic précis et dun risque réduit de traitement par essais et erreurs. Les tests génétiques aident à estimer les risques de développer un cancer au cours de la vie en recherchant des mutations dans les gènes, les chromosomes ou les protéines.
Les lancements et les approbations de produits sont des stratégies couramment adoptées par les entreprises pour élargir leur empreinte mondiale et leur portefeuille de produits. De plus, les acteurs du marché du dépistage du cancer héréditaire se concentrent sur la stratégie de partenariat pour élargir leur clientèle, ce qui leur permet de maintenir leur marque à travers le monde. La part de marché des tests de cancer héréditaire devrait prospérer avec le développement de nouveaux produits innovants par les acteurs du marché. Certains acteurs opérant sur le marché sont Hologic Inc. ; Koninklijke Philips NV; Diagnostics de quête incorporés ; Myriade Génétique, Inc. ; Ambry Génétique ; Laboratoires NéoGénomiques ; Conseiller ; Génétique du cancer Inc. ; Société Invitae ; Myogènes ; Strand Life Sciences Pvt. Ltd.; Société de génomique Pathway ; et CENTOGENE AG.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.
In terms of end user, the global hereditary cancer testing market is segmented into diagnostic centers, hospital, and clinics. Among the above 4 segments, the diagnostic centers segment held the largest market share in 2018.
The hospital segment is estimated to grow at the fastest rate during the forecast period.
Problems in accessing whole genomic data for early detection is the major factor hindering the market growth.
The List of Companies
- Hologic Inc.
- Koninklijke Philips N.V.
- Quest Diagnostics Incorporated
- Myriad Genetics, Inc.
- Cancer Genetics Inc.
- Invitae Corporation
- Myogenes
- Strand Life Sciences Pvt. Ltd.
- Pathway Genomics Corporation
- CENTOGENE AG
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Sep 2019
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Sep 2019
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Sep 2019
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Sep 2019
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Sep 2019
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Sep 2019
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Sep 2019
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)